After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.
A newly published study suggests that women may respond differently than men to some HIV curative interventions that are currently under investigation or, perhaps, that an effective HIV cure for women could differ from a cure for men.
Anthony Fauci Discusses Research Approaches to Sustaining HIV Remission Without Antiretroviral Therapy
Fauci spoke to TheBodyPRO at this year's International AIDS Conference on approaches to HIV remission and durable control of HIV without antiretroviral therapy.
Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.
Why do we lack a cure for HIV infection, and what research is underway to help achieve that goal? A new video from NIAID provides answers.
Three researchers talk about ongoing HIV cure research within the AIDS Clinical Trials Group, treatment interruptions, and when we might see a cure.
On June 6, 2018, without news from the U.S. FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.
NIH Clinical Trial to Track Outcomes of Kidney Transplantation From HIV-Positive Donors to HIV-Positive Recipients
The first large-scale clinical trial to study kidney transplantations between people with HIV has begun at clinical centers across the U.S.
New strategies are here, more are on the way, and the future of ART remains bright, according to W. David Hardy, M.D.
Even a moderately efficacious HIV vaccine could make a significant additional contribution to halting the virus. And for HIV-positive people, a true end to HIV lies not in an epidemiological calculus, but in a cure.